These evens are say at least a year away. There are a couple of very near term upcoming events that should affect the share price before. First one is reasonable confidence that Teva will prevail in the ruling re Copaxone mini-trial on inequitable conduct argument (minor positive). The other is strong data for BG12 from its second phase III (CONFIRM) trial (major negative). After these there's the possibility of tL approval (major positive in the moral aspect).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.